RCS - MGC Pharmaceuticals - Non-Deal Roadshow Presentation December 2023

Argent BioPharma

18/12/2023 09:06

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231218:nRSR1411Xa&default-theme=true

RNS Number : 1411X  MGC Pharmaceuticals Limited  18 December 2023

 

MGC Pharmaceuticals Ltd.

Non-Deal Roadshow Presentation December 2023

18 December 2023

ASX, LSE: MXC

 

 

MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company), a European based
pharmaceutical company specialising in the production and development of
innovative medicines for unmet medical needs, announces the publication of its
non-deal roadshow presentation for December 2023 which may be accessed via the
following link
http://www.rns-pdf.londonstockexchange.com/rns/1411X_1-2023-12-18.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/1411X_1-2023-12-18.pdf)  .

 

-Ends-

 

Authorised for release by the board of directors, for further information
please contact:

 MGC Pharmaceuticals Ltd                                                  MGC Pharmaceuticals Ltd

 Roby Zomer                                                               Rowan Harland

 CEO & Managing Director                                                  Company Secretary

 +61 8 6555 2950                                                          +61 8 6555 2950

 info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)                       info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)
 UK IR/PR Advisers                                                        UK Brokers

 IFC Advisory                                                             Oberon Capital

 Graham Herring / Tim Metcalfe / Zach Cohen                               Aimee McCusker / Adam Pollock

 +44 203 934 6630                                                         +44 203 179 5300

 mgcpharma@investor-focus.co.uk (mailto:mgcpharma@investor-focus.co.uk)   aimeemccusker@oberoninvestments.com
                                                                          (mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
                                                                          (mailto:adampollock@oberoninvestments.com)

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European
pharmaceutical company with a strong commitment to creating accessible and
ethically produced cutting-edge medicines. Our approach combines in-house
research with innovative technologies, all aimed at discovering and producing
treatments for currently unmet medical conditions.

 

The company's founders and executives are distinguished figures in the global
pharmaceutical industry. Our central business strategy revolves around the
development and supply of innovative medicines, responding to the increasing
demand in the medical markets of Europe, North America, and Australasia.

 

MGC Pharma maintains a robust development pipeline that addresses two
prevalent medical conditions, with additional products currently in the
developmental stages. We've established strategic partnerships with renowned
institutions and academia, fostering the optimization of our medicines'
development. These medicines are produced in our EU-GMP Certified
manufacturing facilities, ensuring the highest quality standards.

 

With a growing patient base in key regions like the USA, UK, Australia, and
Ireland, MGC Pharma has also built a global distribution network through a
wide-reaching group of commercial partners. This extensive network places us
in a prime position to supply the global market effectively.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland
and has a global distribution footprint via an extensive network of commercial
partners meaning that it is poised to supply the global market.

 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFDSUAEDSESE